Teva Pharmaceutical Industries (NYSE:TEVA) Issues FY 2025 Earnings Guidance

Key Points

• Teva Pharmaceutical Industries has issued its FY 2025 earnings guidance, expecting an EPS of 2.500-2.600 and revenue between $16.8 billion and $17.2 billion, slightly below consensus estimates.
• The company's stock has received positive ratings from several analysts, with price targets ranging from $20.00 to $24.00, indicating a generally optimistic outlook.
• Teva reported a 0.52 EPS for its latest quarter, surpassing estimates, but with revenues slightly lagging behind expectations, indicating some volatility in business performance.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 2.500-2.600 for the period, compared to the consensus EPS estimate of 2.531. The company issued revenue guidance of $16.8 billion-$17.2 billion, compared to the consensus revenue estimate of $17.0 billion.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a "buy" rating and a $24.00 price objective for the company. UBS Group cut their price objective on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Finally, JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their price objective for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $24.71.

Teva Pharmaceutical Industries Trading Down 2.4%

TEVA traded down $0.37 on Friday, hitting $15.09. The company had a trading volume of 2,284,581 shares, compared to its average volume of 12,167,084. The company has a market cap of $17.30 billion, a PE ratio of -94.29, a PEG ratio of 0.99 and a beta of 0.60. Teva Pharmaceutical Industries has a 12-month low of $12.47 and a 12-month high of $22.80. The company has a quick ratio of 0.74, a current ratio of 1.03 and a debt-to-equity ratio of 2.59. The business's fifty day simple moving average is $16.89 and its 200 day simple moving average is $16.67.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. The business had revenue of $4.18 billion during the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 47.68%. The firm's quarterly revenue was up .3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.61 earnings per share. Equities research analysts expect that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the sale, the executive vice president owned 9,989 shares of the company's stock, valued at $170,012.78. This trade represents a 38.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.49% of the stock is currently owned by insiders.

Institutional Trading of Teva Pharmaceutical Industries

An institutional investor recently raised its position in Teva Pharmaceutical Industries stock. AQR Capital Management LLC grew its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 24.6% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 23,955 shares of the company's stock after acquiring an additional 4,732 shares during the period. AQR Capital Management LLC's holdings in Teva Pharmaceutical Industries were worth $368,000 at the end of the most recent quarter. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.